Lowering Protein in Urine: 3 Methods That Might Help

Summary

Lowering protein in urine, or reducing proteinuria, is a crucial therapeutic goal in managing kidney disease and preventing progression to end-stage renal failure. Proteinuria, characterized by excess protein excretion in urine, often indicates damage to the glomerular filtration barrier within the kidneys and is associated with various chronic conditions including diabetes mellitus, hypertension, and immune-mediated kidney disorders. Persistent proteinuria is not only a marker of renal injury but also an independent risk factor for cardiovascular disease and worsening kidney function, making effective interventions to reduce proteinuria vital for patient outcomes.
This article outlines three primary methods that may help lower proteinuria: dietary adjustments, pharmacological treatments, and lifestyle modifications. Dietary strategies focus on moderating protein and sodium intake to reduce kidney workload and control blood pressure, which can help decrease protein leakage in urine. Pharmacological approaches include the use of renin-angiotensin system inhibitors (ACE inhibitors and ARBs), mineralocorticoid receptor antagonists, calcium channel blockers, and newer agents such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and monoclonal antibodies targeting immune pathways. These medications aim to reduce intraglomerular pressure, modulate immune responses, and protect renal function.
Lifestyle interventions complement medical therapy by promoting cardiovascular health and blood pressure control through regular physical activity, stress management, and adherence to a kidney-friendly diet. Together, these methods contribute to lowering proteinuria, slowing chronic kidney disease progression, and improving long-term health outcomes. Emerging treatments and ongoing research continue to explore novel pharmacological agents and combination therapies to enhance efficacy and minimize adverse effects.
Despite advances, challenges remain in optimizing treatment due to variable patient responses, potential medication side effects such as hyperkalemia, and the need for individualized care plans. Monitoring proteinuria through urine testing remains essential for evaluating treatment effectiveness and guiding therapy adjustments. Continued research is critical to establish evidence-based guidelines and expand therapeutic options for reducing proteinuria and its associated complications.

Causes of Proteinuria

Proteinuria, the presence of excess protein in the urine, typically indicates damage to the kidneys or an underlying medical condition affecting renal function. It results from alterations in the glomerular filtration barrier, which normally prevents proteins from passing into the urine. This barrier’s integrity can be compromised due to changes in size and charge selectivity, often caused by damage to the glomerular capillary wall or increased intraglomerular pressure.
Several chronic diseases are major contributors to proteinuria. Diabetes mellitus is a leading cause, where persistently high blood sugar levels damage the small blood vessels in the kidneys responsible for filtering proteins, resulting in protein leakage. Similarly, hypertension can increase intraglomerular pressure, promoting proteinuria by damaging glomerular structures. Heart disease and infections can also contribute to kidney damage leading to proteinuria.
Proteinuria can be classified into different types based on its origin. Postrenal proteinuria occurs when proteins are added to the urine after it leaves the kidneys, whereas albuminuria—commonly associated with early kidney disease—is characterized by the presence of albumin, a specific protein type, in the urine. Transient proteinuria is intermittent and may resolve without intervention, often triggered by less serious or temporary conditions.
On a molecular level, factors such as increased protease activity and reduced synthesis of proteoglycans compromise the glomerular barrier’s penetrability. Reactive oxygen species and free radicals contribute significantly to the pathogenesis of nephrotic syndromes, while transforming growth factor-beta (TGF-β) promotes fibrosis and glomerulosclerosis by increasing extracellular matrix synthesis.
Furthermore, proteinuria is an independent risk factor for progression to end-stage renal disease, making it essential to identify and address its causes promptly. Emerging research also suggests that alterations in the gut microbiota may influence kidney damage and proteinuria, although probiotic therapies have shown mixed results in clinical settings.

Methods to Lower Protein in Urine

Lowering protein levels in urine, or proteinuria, primarily involves managing the underlying causes and employing a combination of lifestyle changes, medications, and emerging therapies.

Dietary Adjustments

A kidney-friendly diet plays a significant role in reducing proteinuria. Common recommendations include limiting sodium intake to less than 2,300 mg per day to help control blood pressure and fluid retention, as excessive salt can exacerbate these conditions. Additionally, moderating dietary protein intake is advised because high protein consumption can strain the kidneys and increase protein leakage into the urine. Controlling blood sugar levels through diet is also important, especially in diabetic patients, to protect kidney function.

Medications

Several classes of medications have been shown to effectively reduce proteinuria by targeting blood pressure control, immune modulation, and kidney protection:
– Renin-Angiotensin System Inhibitors: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are first-line therapies for reducing proteinuria. They lower intraglomerular pressure by inhibiting angiotensin II–mediated efferent arteriole vasoconstriction, which decreases protein leakage independent of their blood pressure-lowering effects. ARBs may be as effective or even more effective than ACEIs in some cases. Careful monitoring of serum creatinine and potassium is necessary, as these drugs can cause hyperkalemia and renal function changes.
– Mineralocorticoid Receptor Antagonists (MRAs): MRAs can further reduce proteinuria, particularly in diabetic kidney disease, though they carry an increased risk of hyperkalemia. Current guidelines recommend adding nonsteroidal MRAs in patients with persistent albuminuria despite maximal ACEI or ARB therapy, provided renal function and potassium levels are adequate.
– Calcium Channel Blockers: Non-dihydropyridine calcium channel blockers (NDCCBs), such as verapamil, efonidipine, and benedipine, have demonstrated greater proteinuria reduction compared to dihydropyridine calcium channel blockers. Newer NDCCBs acting on N- and T-type calcium channels, often used alongside ARBs, show promising results in lowering proteinuria.
– Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Initially approved for glycemic control in type 2 diabetes, SGLT2 inhibitors have shown benefits in reducing proteinuria and slowing chronic kidney disease progression in patients with and without diabetes.
– Immunosuppressive Agents and Monoclonal Antibodies: For proteinuria related to immune-mediated conditions such as IgA nephropathy and nephrotic syndrome, corticosteroids, rituximab, cyclophosphamide, and cyclosporine are used to reduce inflammation and immune activity. Newer agents like sibeprenlimab, a humanized IgG2 monoclonal antibody targeting APRIL implicated in IgA nephropathy, have shown efficacy in decreasing proteinuria and are currently under FDA Priority Review. Obinutuzumab and repository corticotrophin (ACTH) injections also offer alternative immunosuppressive options for difficult-to-treat proteinuric kidney diseases.

Lifestyle Adjustments

Sustained lifestyle modifications are essential complements to medical therapy in lowering proteinuria.
– Regular physical activity to improve cardiovascular and renal health.
– Stress management to aid in blood pressure control.
– Maintaining a mindset of daily movement and consistently following a healthy, low-sodium diet.
Monitoring blood pressure regularly and maintaining communication with healthcare providers allows for timely medication adjustments and helps prevent kidney damage.
Together, these methods contribute to reducing proteinuria, protecting kidney function, and improving long-term outcomes for patients with proteinuric kidney diseases.

Monitoring and Diagnosis

Proteinuria is typically identified through urine testing, which measures the amount of protein excreted in the urine. A commonly used method is the dipstick test, where a chemically coated strip changes color in the presence of elevated protein levels. More precise measurements involve the urine albumin-to-creatinine ratio (UACR), which compares the concentration of albumin to creatinine in a urine sample. A normal UACR is less than 30 mg/g, and values above this threshold can indicate chronic kidney disease (CKD), prompting further evaluation.
In clinical practice, spot urine samples, particularly the first morning urine, are often used to estimate proteinuria by determining the protein-to-creatinine ratio (PCR). This approach has been shown to be as effective as 24-hour urine collections for predicting clinical outcomes and is simpler and more cost-effective, especially in pediatric populations. However, variability in laboratory measurements, lack of standardized reference materials, and inconsistent reporting units pose challenges to uniform interpretation and comparison of proteinuria results across different settings.
Guidelines for the evaluation and monitoring of proteinuria vary internationally but increasingly recommend the use of urine ACR for defining, staging, and monitoring CKD. Regular monitoring of proteinuria is crucial, particularly in patients with CKD, to guide treatment decisions such as the initiation or adjustment of renin-angiotensin system inhibitors (RASi) and nonsteroidal mineralocorticoid receptor antagonists (MRAs). Effective management relies on adherence to clinical guidelines, which audits suggest remains suboptimal in many healthcare settings.
Patients diagnosed with proteinuria often require ongoing follow-up care by primary care physicians, internists, or nephrologists, depending on the underlying cause and severity. Monitoring involves periodic urine tests to assess protein levels, evaluation of kidney function, and management of associated risk factors. Early detection and continuous monitoring are essential to prevent progression of kidney damage and optimize patient outcomes.

Potential Complications of Untreated Proteinuria

Proteinuria often signals underlying kidney problems and can be an important marker of kidney damage. If left untreated, persistent proteinuria may indicate progressive renal injury, increasing the risk of advancing chronic kidney disease and eventual renal failure. This progression can significantly impair kidney function over time, leading to serious complications.
One notable complication of untreated proteinuria is the heightened risk of cardiovascular disease. Proteinuria is frequently associated with hyperlipidemia, which together contribute to an increased risk for atherosclerotic disease. Although dietary measures alone are typically insufficient to control hyperlipidemia in these patients, medication such as statin therapy is often required to manage this risk factor effectively.
Moreover, persistent proteinuria can exacerbate other morbidities commonly observed in chronic kidney disease (CKD), including renal bone disease, vascular calcification, and anemia. The quality of evidence regarding the effectiveness of various interventions to reduce proteinuria and mitigate these complications varies, with many studies limited by imprecision and bias.

Research and Emerging Treatments

Recent research into lowering proteinuria has focused on novel pharmacological agents, nutritional interventions, and combination therapies aimed at slowing the progression of kidney disease and reducing protein leakage in the urine.

Novel Pharmacological Agents

One promising investigational drug is Sibeprenlimab, a humanized IgG2 monoclonal antibody that targets and neutralizes a proliferation-inducing ligand (APRIL), which plays a role in the pathogenesis of IgA nephropathy. Clinical studies have demonstrated that Sibeprenlimab effectively decreases proteinuria in adults with IgA nephropathy who are at risk of rapid disease progression. This agent is currently under Priority Review by the FDA, with a target action date set for November 2025.
Other emerging pharmacological options include nonsteroidal mineralocorticoid receptor antagonists (MRAs), which are recommended by current KDIGO guidelines for patients with an estimated glomerular filtration rate (eGFR) above 25 mL/min/1.73 m² and normal serum potassium levels who have persistent albuminuria despite maximal tolerated angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy. These agents reduce proteinuria while carrying a lower risk of hyperkalemia compared to steroidal MRAs, which have been associated with a threefold to eightfold increased risk of this side effect.
In addition, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in reducing proteinuria and may slow kidney function decline, particularly in patients with type 2 diabetes mellitus. Endothelin receptor antagonists also represent a target for reducing albuminuria, although randomized controlled trials (RCTs) have yet to provide conclusive evidence of their efficacy in this context.

Nutritional and Lifestyle Approaches

Medical nutrition therapy remains a critical component of managing proteinuria and slowing chronic kidney disease progression. Protein restriction is the main dietary intervention studied, although evidence from randomized controlled trials is limited and often controversial. Adjusting micro and macronutrient intake and adopting specific dietary styles, such as the DASH (Dietary Approaches to Stop Hypertension) diet, have been explored for their potential benefits on blood pressure and proteinuria reduction.
Metabolomic studies have identified biomarkers linked to dietary patterns, suggesting that pathways related to glutamate metabolism may contribute to the blood pressure–lowering effects of the DASH diet, which in turn could reduce proteinuria through improved vascular function. However, more rigorous clinical trials are needed to establish the direct impact of these nutritional interventions on proteinuria outcomes.

Combination Therapies and Future Directions

Current evidence supports the use of ACE inhibitors and ARBs as first-line treatments to reduce proteinuria, yet their underuse persists due to concerns about adverse effects such as hyperkalemia and renal function decline. Meta-analyses call for long-term trials comparing combination therapy versus monotherapy with these agents to evaluate efficacy in reducing proteinuria and delaying end-stage renal disease, while closely monitoring adverse events.
Emerging strategies include combining pharmacological agents like Sibeprenlimab or nonsteroidal MRAs with established treatments and nutritional management to achieve greater proteinuria reduction. This integrative approach aims to address the multifactorial pathophysiology of proteinuric nephropathies, improving patient outcomes through personalized medicine.

The content is provided by Blake Sterling, Direct Bulletins